EVEREST MED rose over 4%, with multiple management members increasing their shareholding, totaling over 38 million

AASTOCKS
2025.12.15 01:39

EVEREST MED (01952.HK) announced that its non-executive director and honorary chairman Fu Wei, executive director and chairman of the board Wu Yifang, executive director and CEO Luo Yongqing, and executive director, president, and CFO He Ying, respectively purchased 339,000 shares, 277,000 shares, 132,500 shares, and approximately 98,200 shares of the company's ordinary shares in the market, with a total cost exceeding HKD 38 million, at an average price of approximately HKD 45.01 per share.

In addition, the company's major shareholder Kangqiao Capital has further committed to increasing its shareholding ratio by no more than 1% cumulatively over the next 3 to 6 months.

EVEREST MED opened 3.03% higher today, reaching a high of HKD 47.72. It is currently reported at HKD 46.7, up 4.15%, with a trading volume of 2.076 million shares, involving HKD 97.4036 million

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.